Artivion, Inc. (AORT)

NYSE: AORT · IEX Real-Time Price · USD
18.48
0.22 (1.20%)
May 18, 2022 4:00 PM EDT - Market closed
Market Cap742.93M
Revenue (ttm)304.96M
Net Income (ttm)-15.09M
Shares Out40.20M
EPS (ttm)-0.38
PE Ration/a
Forward PE357.14
Dividendn/a
Ex-Dividend Daten/a
Volume332,888
Open18.31
Previous Close18.26
Day's Range18.20 - 19.12
52-Week Range15.44 - 31.78
Beta1.55
AnalystsBuy
Price Target28.76 (+55.6%)
Earnings DateMay 5, 2022

About AORT

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment...

IndustryMedical Devices
IPO DateFeb 11, 1993
CEOJames Mackin
Employees1,300
Stock ExchangeNYSE
Ticker SymbolAORT
Full Company Profile

Financial Performance

In 2021, Artivion's revenue was $298.84 million, an increase of 18.01% compared to the previous year's $253.23 million. Losses were -$14.83 million, -11.08% less than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for AORT stock is "Buy." The 12-month stock price forecast is 28.76, which is an increase of 55.63% from the latest price.

Price Target
$28.76
(55.63% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Artivion to Participate in the UBS 2022 Global Healthcare Conference

ATLANTA , May 16, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in the upcoming UBS...

2 days ago - PRNewsWire

Artivion Reports First Quarter 2022 Financial Results

Achieved revenue of $77.2 million in the first quarter 2022 versus $71.1 million in the first quarter of 2021, an increase of 8.6% on a GAAP basis and 11.2% on a non-GAAP constant currency basis ATLANTA...

1 week ago - PRNewsWire

ArtivionAnnounces Release Date and Teleconference Call Details for First Quarter 2022 Financial Results

ATLANTA, April 21, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2022 financial results w...

3 weeks ago - PRNewsWire

Artivion to Participate in the 21st Annual Needham Virtual Healthcare Conference

ATLANTA, March 31, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming 21...

1 month ago - PRNewsWire

Artivion Publishes Inaugural Corporate Responsibility Report

ATLANTA, March 14, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today published its inaugural Corporate Responsibility Repo...

2 months ago - PRNewsWire

Artivion to Host Investor & Analyst Day on March 23, 2022

ATLANTA, March 9, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will host an Investor & Analyst Day ...

2 months ago - PRNewsWire

Artivion to Participate in the Oppenheimer 32nd Annual Healthcare Conference

ATLANTA, March 3, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the up...

2 months ago - PRNewsWire

Artivion (AORT) Reports Break-Even Earnings for Q4

Artivion (AORT) delivered earnings and revenue surprises of 100% and 1.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Artivion Reports Fourth Quarter and Full Year 2021 Financial Results

ATLANTA, Feb. 17, 2022 /PRNewswire/ -- Fourth Quarter and Recent Business Highlights: Achieved record revenue of $79.4 million in the fourth quarter 2021 versus $67.9 million in the fourth quarter of 20...

3 months ago - PRNewsWire

Earnings Preview: Artivion (AORT) Q4 Earnings Expected to Decline

Artivion (AORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2021 Financial Results

ATLANTA, Feb. 3, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2021 financ...

3 months ago - PRNewsWire

CryoLife Announces Corporate Rebranding and Changes Name to Artivion

ATLANTA, Jan. 18, 2022 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to...

4 months ago - PRNewsWire

A Trio of Low Price-Sales Ratio Stocks

Value investors may find the following stocks to be attractive opportunities, as they have low price-sales ratios compared to the S&P 500 and good profitability.

Other symbols:AROCVSEC
6 months ago - GuruFocus

CryoLife to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum

ATLANTA, Nov. 9, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that members of management will host one-on-on...

6 months ago - PRNewsWire

Wall Street Analysts Think CryoLife (CRY) Could Surge 51%: Read This Before Placing a Bet

The mean of analysts' price targets for CryoLife (CRY) points to a 50.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i...

6 months ago - Zacks Investment Research

CryoLife (CRY) Tops Q3 Earnings Estimates

CryoLife (CRY) delivered earnings and revenue surprises of 420.00% and -0.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Recap: Cryolife Q3 Earnings

Cryolife (NYSE:CRY) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:05 PM. Here's what investors need to know about the announcement.

6 months ago - Benzinga

CryoLife Reports Third Quarter 2021 Financial Results

ATLANTA, Nov. 4, 2021 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, ...

6 months ago - PRNewsWire

Earnings Preview: CryoLife (CRY) Q3 Earnings Expected to Decline

CryoLife (CRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2021 Financial Results

ATLANTA, Oct. 20, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2021 financial results wil...

6 months ago - PRNewsWire

Anthony Semedo Joins CryoLife Board of Directors

ATLANTA, Sept. 22, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today the appointment of Anthony "Tony" Semedo to ...

7 months ago - PRNewsWire

CryoLife to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

ATLANTA, Aug. 31, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming Morg...

8 months ago - PRNewsWire

CryoLife to Participate in Upcoming Virtual Investor Conferences

ATLANTA, Aug. 2, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in two upcoming virtu...

9 months ago - PRNewsWire

CryoLife (CRY) Reports Q2 Loss, Tops Revenue Estimates

CryoLife (CRY) delivered earnings and revenue surprises of -20.00% and 5.76%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Cryolife: Q2 Earnings Insights

Shares of Cryolife (NYSE:CRY) rose 2.9% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 700.00% year over year to $0.12, which beat the estimate ...

9 months ago - Benzinga